Bone derived hormones in relation to insulin resistance in type 2 diabetes and pre-diabetes / (Record no. 174372)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 08093namaa22004571i 4500 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OSt |
| 005 - أخر تعامل مع التسجيلة | |
| control field | 20251005132843.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 250929s2025 ua a|||frm||| 000 0 eng d |
| 040 ## - CATALOGING SOURCE | |
| Original cataloguing agency | EG-GICUC |
| Language of cataloging | eng |
| Transcribing agency | EG-GICUC |
| Modifying agency | EG-GICUC |
| Description conventions | rda |
| 041 0# - LANGUAGE CODE | |
| Language code of text/sound track or separate title | eng |
| Language code of summary or abstract | eng |
| -- | ara |
| 049 ## - Acquisition Source | |
| Acquisition Source | Deposit |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.466 |
| 092 ## - LOCALLY ASSIGNED DEWEY CALL NUMBER (OCLC) | |
| Classification number | 616.466 |
| Edition number | 21 |
| 097 ## - Degree | |
| Degree | Ph.D |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| Local Call Number | Cai01.11.18.Ph.D.2025.Ta.B |
| 100 0# - MAIN ENTRY--PERSONAL NAME | |
| Authority record control number or standard number | Tasneem Khaled Mostafa Mahmoud , |
| Preparation | preparation. |
| 245 10 - TITLE STATEMENT | |
| Title | Bone derived hormones in relation to insulin resistance in type 2 diabetes and pre-diabetes / |
| Statement of responsibility, etc. | by Tasneem Khaled Mostafa Mahmoud ; Supervisors Prof. Dr. Hala Esameldin Mohamed Kahla, Prof. Dr. Olfat Gamil Shaker, Dr. Mona Yousry Helmy, Dr. Yasmine Abd Elfatah Mohamed. |
| 246 15 - VARYING FORM OF TITLE | |
| Title proper/short title | العلاقة بين الهرمونات المشتقة من العظام ومقاومة الأنسولين في مرض السكري من النوع الثانى ومرحلة ما قبل مرض السكري |
| 264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | 2024. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 134 pages : |
| Other physical details | illustrations ; |
| Dimensions | 25 cm. + |
| Accompanying material | CD. |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Source | rda content |
| 337 ## - MEDIA TYPE | |
| Media type term | Unmediated |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | volume |
| Source | rdacarrier |
| 502 ## - DISSERTATION NOTE | |
| Dissertation note | Thesis (Ph.D)-Cairo University, 2025. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE | |
| Bibliography, etc. note | Bibliography: pages 114-134. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | Background: Type 2 diabetes has fallen into the leading causes of disability and death worldwide<br/>Obesity is associated with chronic inflammatory disorders, due to irregular secretion of adipokines and stimulation of pro-inflammatory signaling pathways. These adipokines inhibit insulin receptors, decreasing glucose transport with subsequent hyperglycemia. <br/>Prediabetes is characterized by decreased insulin sensitivity and impaired insulin secretion with glycemic values between normal and diabetics.<br/>Bone is becoming recognized for its endocrine function. Three of these bone-derived hormones: osteocalcin, lipocalin 2, and sclerostin play vital roles in the pathophysiological process of developing cardiometabolic syndromes such as type 2 diabetes and cardiovascular disease. <br/>Aim and objectives: To study the relation between bone derived hormones and insulin resistance in type 2 diabetes and pre-diabetes. <br/>Subjects and methods: This study was case control study conducted on patients selected from the outpatient internal medicine, diabetes and endocrinology clinics of Kasr Al-ainy hospital school of medicine. Contributors were assigned to 4 groups: Group 1: 31 Obese type 2 diabetic patients. <br/>Group 2: 31 non-obese type 2 diabetic patients. Group 3: 31 pre-diabetic patients. Group 4: 31 healthy age and sex-matched control individuals. <br/>Laboratory tests included: fasting blood sugar, 2h postprandial blood glucose, hbA1c, lipid profile, Serum Osteocalcin and lipocalin levels were measured for all groups, in addition to BMI and waist circumference.<br/>Result: Neutrophil Gelatinase Associated lipocalin was significantly lower among diabetics (non obese /obese) than controls and it was significantly higher among prediabetics than controls.<br/>Osteocalcin level was higher in diabetics than prediabetics than controls but without statistically significant results.<br/>In our study, there is a significant positive correlation between osteocalcin and (height, waist circumference and lipocalin2) among diabetics. <br/>There is a significant positive correlation between osteocalcin and (HbA1c and lipocalin2) among prediabetics. There is a significant negative correlation between osteocalcin and (total cholesterol and 2HrPP test). <br/>There is a significant negative correlation between Neutrophil Gelatinase Associated lipocalin and (fasting blood sugar, 2 hours post-prandial blood sugar and insulin level) and a significant positive correlation with osteocalcin among prediabetics. <br/>NGAL at cut-off points of ≤8.3 showed good sensitivity and specificity for predicting diabetes. <br/>Triglyceride level was the most important predictor of prediabetes. Neutrophil gelatinase associated lipocalin, triglyceride level and insulin level were the most important predictor of diabetes<br/>Conclusion: In conclusion, Neutrophil Gelatinase Associated lipocalin was significantly lower among diabetics (non obese /obese) than controls. It was significantly higher among prediabetics than controls. Osteocalcin level was higher in diabetics than prediabetics than controls but without statistically significant results. |
| 520 #3 - SUMMARY, ETC. | |
| Summary, etc. | السكري هو مرض مزمن يتميز بارتفاع مستويات الجلوكوز في الدم، مصحوبًا باضطراب في التمثيل الغذائي للدهون والبروتينات. السكري من النوع الثاني (T2D)، وهو الشكل الأكثر شيوعًا للسكري، أصبح أحد الأسباب الرئيسية للإعاقة والموت في جميع أنحاء العالم. في السكري من النوع الثاني، لا تستجيب خلايا الجسم بشكل فعال للأنسولين. ويعرف هذا بمقاومة الأنسولين.<br/>أظهرت الدراسات المتزايدة أن المواد المشتقة من العظم تنظم التوازن الطاقي عن طريق تعديل حساسية الأنسولين، السلوك الغذائي و تأثيره عالخلايا الدهنية و يمكن استخدامها في تشخيص وعلاج ومنع الأمراض المتعلقة بالأيض مثل هشاشة العظام، السمنة ومرض السكري.<br/>تم اكتشاف أن ثلاثة من هذه الهرمونات العظمية وهي الأوستيوكالسين، الليبوكالين ٢ ،والسكليرواستين، تلعب أدوارًا حيوية في المتلازمات القلبية الأيضية مثل السكري من النوع الثاني وأمراض القلب والأوعية الدموية. أظهرت الأبحاث الأخيرة أن الليبوكالين ٢ (LCN2) الذي تفرزه الخلايا البانية للعظم هو جزء من نظام هرموني مهم. <br/>كما أفادت دراسة حديثة أن مستويات الليبوكالين كانت مرتفعة لدى النساء المصابات بمرض السمنة ويمكن استخدامها كإشارة مبكرة للإصابة بمرض السكري من النوع الثاني. يقوم الليبوكالين بدور في مرض السمنة من خلال تأثيره على الشهية وتعزيزه لوظيفة خلايا بيتا، كما أنه يواجه مقاومة الأنسولين ويمنع الإصابة بالسكري. لذلك، يُقترح أن الليبوكالين يلعب دورًا وقائيًا في حدوث السمنة ومقاومة الأنسولين.<br/>هدفت هذه الدراسة إلى دراسة العلاقة بين الهرمونات المشتقة من العظم ومقاومة الأنسولين في مرض السكري من النوع الثاني ومرض ما قبل السكري . تم إجراؤها على المرضى الذين تم اختيارهم من عيادات الطب الباطني وعيادات السكري والغدد الصماء في مستشفى قصر العيني بكلية الطب (جامعة القاهرة). تم تقسيم المشاركين إلى ٤ مجموعات |
| 530 ## - ADDITIONAL PHYSICAL FORM AVAILABLE NOTE | |
| Issues CD | Issues also as CD. |
| 546 ## - LANGUAGE NOTE | |
| Text Language | Text in English and abstract in Arabic & English. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Diabetes |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | السكري |
| 653 #1 - INDEX TERM--UNCONTROLLED | |
| Uncontrolled term | Bone Derived Hormones |
| -- | Insulin Resistance, |
| -- | Type 2 Diabetes |
| -- | Pre-diabetes. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Hala Esameldin Mohamed Kahla |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Olfat Gamil Shaker |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mona Yousry Helmy |
| Relator term | thesis advisor. |
| 700 0# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Yasmine Abd Elfatah Mohamed |
| Relator term | thesis advisor. |
| 900 ## - Thesis Information | |
| Grant date | 01-01-2025 |
| Supervisory body | Hala Esameldin Mohamed Kahla |
| -- | Olfat Gamil Shaker |
| -- | Mona Yousry Helmy |
| -- | Yasmine Abd Elfatah Mohamed |
| Universities | Cairo University |
| Faculties | Faculty of Medicine |
| Department | Department of Internal Medicine |
| 905 ## - Cataloger and Reviser Names | |
| Cataloger Name | Shimaa |
| Reviser Names | Eman Ghareb |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | Dewey Decimal Classification |
| Koha item type | Thesis |
| Edition | 21 |
| Suppress in OPAC | No |
| Source of classification or shelving scheme | Home library | Current library | Date acquired | Inventory number | Full call number | Barcode | Date last seen | Effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|
| Dewey Decimal Classification | المكتبة المركزبة الجديدة - جامعة القاهرة | قاعة الرسائل الجامعية - الدور الاول | 29.09.2025 | 92058 | Cai01.11.18.Ph.D.2025.Ta.B | 01010110092058000 | 29.09.2025 | 29.09.2025 | Thesis |